Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts

Eberhard-karls-universitat Tubingen

Latifa Zekri-Metref

Helmut Salih

Gundram Jung

Fabian Vogt

Isabelle Ehnes

Martin Pflügler

The present invention provides a novel PSMA binding antibody termed 10B3 and pharmaceutical and diagnostic uses of the antibody 10B3. The PSMA antibody 10B3 does not cross-compete with the state of the art PMSA binding antibody J591 and has a reduced induction of antigen shift compared to J591 and a unique reactivity with squamous cell carcinoma (SCC) cells of different origin.

PSMA binding antibody and uses thereof

The present invention provides novel human fins related tyrosine kinase 3 (FLT) antigen binding proteins, such as antibodies, having improved FLTbinding affinity, and/or anti-tumor activity. The FLTantibodies of the invention were generated by mutation of a parent FLTantibody and tested in in vitro in binding assays as well as in vivo in a mouse tumor model and in human patient tumor samples. The antibodies of the invention are provided as monospecific constructs or in a bispecific FLT×CDantibody format and show excellent target affinity and/or tumor cell killing. The present invention also relates methods for producing the antigen binding proteins of the invention as well as nucleic acids encoding them, vectors for and host cells for their expression. The invention further relates to methods of treating or diagnosing a disease such as leukemia using an FLTantigen binding protein (ABP) of the invention.

Anti-FLTantigen binding proteins

Growing community of inventors

Tübingen, Germany

Latifa Zekri-Metref